DSIP Reconstitution Calculator

No. DSIP is not FDA-approved for any indication. It is one of the peptides routinely identified in illegally distributed gray-market products, and a 2026 clinical-trial review of therapeutic peptides including DSIP notes a current lack of clinical trials. The only human trials are small, decades old, and produced mixed results.

Mixed evidence, and effect sizes are uncertain. A double-blind, placebo-controlled 7-night trial in 14 chronic insomniacs reported substantially improved sleep after the first dose, persisting into a placebo post-treatment night, plus improved daytime alertness. A second double-blind trial in 16 chronic insomniacs (IV 25 nmol/kg for 3 nights) found only weak gains in sleep efficiency and latency and concluded short-term DSIP is "not likely to be of major therapeutic benefit". Animal studies consistently show sleep promotion (NREM sleep in rabbits, REM in cats) but with bell-shaped dose-response curves, and a DSIP fusion peptide restored melatonin, serotonin, dopamine and glutamate balance in insomnia-model mice. Whether endogenous DSIP acts as a true physiological sleep factor remains disputed.

Human trials used intravenous DSIP at 25 nmol/kg (≈21 µg/kg; ≈1.7 mg per 80 kg adult). Subcutaneous dosing is active in animals too (100 µg/kg s.c. in cats; 1 mg/kg s.c. in rabbits), and intranasal DSIP at 120 µg/kg was effective in rats. Intact DSIP crosses the blood-brain barrier by non-saturable passive diffusion, so route affects kinetics rather than central access. Dosing is non-linear: DSIP shows a parabolic dose-response, meaning doses above the effective window become less active. Plasma half-life is very short (about 4 min in dogs and 2 min in rats, with rapid enzymatic degradation) so effects depend on downstream central actions rather than sustained blood levels. Community protocol: subcutaneous 100-300 µg 30-60 min before bed, or intranasal 100-200 µg, rarely exceeding 500 µg (community protocol).

The clearest safety exclusion is ischemia-related: in animal models, DSIP or its analogue KND administered during ongoing cardiac or cerebral artery occlusion produced 100% mortality; protective effects occurred only when given during reperfusion. Do not use around suspected stroke, heart attack, or ischemia (animal). Apart from this, days-to-weeks of IV DSIP in human trials proceeded without reported serious adverse events. DSIP-like material occurs naturally in human milk, indicating routine infant exposure. No human data exist for use during pregnancy or breastfeeding; avoid in both (practitioner consensus).

Published human courses are short: 3 nights, 7 nights, or 5 daily injections followed by injections every 48-72 h in a chronic-pain pilot. No long-term human efficacy or safety data exist. Community protocols cycle 2-4 weeks on followed by 1-2 weeks off; dose escalation is discouraged because of the bell-shaped dose-response (community protocol).

DSIP is not a sedative-hypnotic. It shifts sleep architecture (NREM/REM) and neurotransmitter balance (including melatonin, serotonin, dopamine, and glutamate) rather than pharmacologically forcing sleep. It also has non-sleep actions: pain reduction in a chronic headache/pain pilot and blunted naloxone-precipitated withdrawal in morphine-dependent mice. Unlike conventional hypnotics, higher DSIP doses can be less effective. For clinically significant insomnia, melatonin and prescription hypnotics have stronger human evidence; DSIP is best treated as an experimental adjunct.

Yes. DSIP degrades and aggregates in plasma and serum, and its half-life in biological fluids is minutes. Store lyophilized vials frozen or refrigerated, protected from light; after reconstitution with bacteriostatic water, refrigerate and use within about 30 days (community protocol). Carry reconstituted DSIP in an insulated cool pack when traveling. Legality varies by jurisdiction (DSIP sold through research channels is not FDA-approved).